TopoTarget gets key US and European patents
Danish biotechnology company TopoTarget AS says it has been granted a key US patent relating to the use of valproic acid in the treatment of cancer. The patent, number 7,265,154, is valid until February 2022, and covers use of the agent and close derivatives, in all major types of cancer.
Company chief executive Peter Jensen said that the patent provides the firm with a strong position for its Baceca, Avugane and Savicol products, which are in Phase II development for various indications including skin diseases and familial adenomatous polyposis. Prof Jensen added that "clinical data we have collected to now supports our belief that there is a clear opportunity in repurposing VPA in order to help patients with different types of skin cancer including basal cell carcinoma where we recently published positive Phase II data."
European HDAC patent
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze